Analysis GENIX PHARMACEUTICALS CORP. (GENPF)
5/27/2024
Analysis of GENIX PHARMACEUTICALS CORP. (GENPF)
GENIX PHARMACEUTICALS CORP. (GENPF) has been showing a consistent price of 0.02600 over the past few days. The Relative Strength Index (RSI) indicator is quite low at 13.99, indicating an oversold condition. The Moving Average Convergence Divergence (MACD) indicator has been negative, with the MACD line below the signal line, suggesting a bearish trend.The Moving Average (MA) indicator is also below the current price, indicating a bearish signal. The Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) are all above the current price, further supporting the bearish outlook.
Overall, based on the technical indicators, GENIX PHARMACEUTICALS CORP. seems to be in a bearish trend with oversold conditions. Traders and investors may want to exercise caution and wait for a potential reversal signal before considering any buying opportunities.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a wide range of opinions on the future price of the security, with the low end at $164, the high end at $250, and the average at $202.26. The current price is $191.57, which is below the average and median forecasted prices.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided yet. The previous results were reported on February 27, 2025, through the Transfer Agent. Before that, on January 31, 2025, the results were released after hours. The results for the quarter ending on October 31, 2024, were not provided on time. However, on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.33.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits for a specific company.In terms of financials, the company has a strong operating cash flow and levered free cash flow. The balance sheet shows a healthy current ratio, but a relatively high total debt to equity ratio. The profit margin and operating margin are both positive, indicating profitability. The company's fiscal year ends in September 2023, with notable figures such as EBITDA, revenue, and net income.
Moving on to stock statistics, we see details such as short ratio, float shares, shares outstanding, and insider and institutional ownership percentages. The company's stock price summary includes metrics like beta, moving averages, and the 52-week high and low prices.
Valuation metrics provide insights into the company's valuation multiples, such as P/E ratios, PEG ratio, price to book, price to sales, and enterprise value multiples.
Lastly, dividends and splits information includes dividend dates, split history, dividend rates, and dividend yields. The company has a payout ratio and offers both forward and trailing annual dividend yields.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential need for cost management strategies.
3. The gross profit margin has remained relatively stable over the years, indicating efficient cost control measures.
4. The operating income has shown a positive trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
5. The net income has also been increasing consistently, from $57.4 billion in 2020 to $97 billion in 2023.
6. The company has been able to maintain a healthy EBITDA margin, reflecting strong operational performance.
7. The company's tax expenses have also increased over the years, suggesting higher profitability.
8. The basic and diluted earnings per share have shown an upward trend, indicating improved profitability per share.
9. Overall, the financial performance of the company in terms of revenue and profitability has been positive and improving over the years.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $290,437,000,000 in 2023.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, but there are fluctuations in certain areas that may require further analysis and attention.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Year Ago EPS: $1.26
- Number of Analysts: 26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Year Ago EPS: $1.46
- Number of Analysts: 25
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Year Ago EPS: $6.13
- Number of Analysts: 39
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Year Ago EPS: $6.59
- Number of Analysts: 39
Based on these estimates, we can see a generally positive trend in the expected earnings per share for both the upcoming quarters and the next two years. The average estimates show growth compared to the previous year's EPS in each period, indicating a positive outlook from analysts regarding the company's performance.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 11%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the next 5 years compared to the past 5 years. The company is projected to experience steady growth in the upcoming quarters and years, indicating a positive outlook according to analyst consensus.
MACD of GENPF
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
